Zelira-Hope 1

Zelira Therapeutics is a global biopharmaceutical company specializing in the development and clinical validation of cannabinoid-based medicines. The company operates a unique business model that combines traditional pharmaceutical drug development with the rapid commercialization of clinically-validated branded products. Its portfolio features the HOPE® line for autism spectrum disorder and Zenivol® for chronic insomnia, both of which have undergone clinical trials to demonstrate safety and efficacy. Zelira's research pipeline also targets chronic pain and dermatological conditions, leveraging partnerships with world-leading medical institutions to accelerate the path from discovery to market.